十二因子抑制剂在预防遗传性血管发作的潜力
James K Y Hooi1, Jane C Y Wong1, Philip H Li1,2
1Division of Rheumatology & Clinical Immunology, Department of Medicine,University of Hong Kong, Pokfulam, Hong Kong SAR, China.
Expert opinion on biological therapy
|May 24, 2025
概括
XII因子 (FXII) 抑制剂为遗传性血管 (HAE) 提供了一种新型的预防性治疗方法,向上游的接触系统. 加拉达西马布的早期结果显示,它有望提高HAE管理的有效性和可访问性.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 遗传性血管 (HAE) 涉及由于布拉迪基宁通路失调而导致的复发性胀.
- 目前针对布拉迪基宁或C1-酶抑制剂的HAE治疗方法在有效性和可访问性方面存在局限性.
研究的目的:
- 审查XII因子 (FXII) 在HAE病变发生中的作用.
- 评估FXII抑制作为HAE的新型预防性治疗策略.
主要方法:
- 临床前和临床研究结果的综合.
- 对FXII抑制剂的真实世界观察数据的分析.
- 对加拉达西马布的疗效和安全性概况的评估.
主要成果:
- FXII抑制针对的是上游的接触系统,解决了当前治疗方法的局限性.
- 加拉达西马布在HAE管理中展示了潜在的疗效和实际益处.
- FXII被确定为HAE.的可行和可用药物的目标.
结论:
- 抑制FXII是HAE的一个有希望的策略,解决了预防的未满足需求.
- 需要进一步研究FXII抑制剂的长期安全性,成本和可获得性.
- 抑制FXII可能会促进个性化护理,并改善HAE患者的生活质量.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
934
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
934
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
656
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
656
Venous Thrombosis III: Interprofessional Care
29
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
29
Antihypertensive Drugs: Direct Renin Inhibitors
850
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
850
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
527
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
527


